{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,11]],"date-time":"2026-09-11T10:32:54Z","timestamp":1789122774478,"version":"build-2803163510"},"reference-count":25,"publisher":"Springer Science and Business Media LLC","issue":"9","license":[{"start":{"date-parts":[[2026,6,22]],"date-time":"2026-06-22T00:00:00Z","timestamp":1782086400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2026,6,22]],"date-time":"2026-06-22T00:00:00Z","timestamp":1782086400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Bone Marrow Transplant"],"published-print":{"date-parts":[[2026,9]]},"DOI":"10.1038\/s41409-026-02946-6","type":"journal-article","created":{"date-parts":[[2026,6,22]],"date-time":"2026-06-22T20:24:35Z","timestamp":1782159875000},"page":"1133-1140","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Bendamustine-based lymphodepletion prior to CAR T-cell therapy: a systematic review"],"prefix":"10.1038","volume":"61","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-8123-8405","authenticated-orcid":false,"given":"Mostafa F.","family":"Mohammed Saleh","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ahmed","family":"Abdrabou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ahmed","family":"Alnughmush","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Syed Osman","family":"Ahmed","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3942-7370","authenticated-orcid":false,"given":"Mahmoud","family":"Aljurf","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4498-3865","authenticated-orcid":false,"given":"Riad","family":"El Fakih","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,6,22]]},"reference":[{"key":"2946_CR1","doi-asserted-by":"publisher","first-page":"7844","DOI":"10.1002\/cam4.5551","volume":"12","author":"S Abbasi","year":"2023","unstructured":"Abbasi S, Totmaj MA, Abbasi M, Hajazimian S, Goleij P, Behroozi J, et al. Chimeric antigen receptor T (CAR-T) cells: novel cell therapy for hematological malignancies. Cancer Med. 2023;12:7844\u201358.","journal-title":"Cancer Med"},{"key":"2946_CR2","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2022.984864","volume":"13","author":"Z Zhou","year":"2022","unstructured":"Zhou Z, Tao C, Li J, Tang JC, Chan AS, Zhou Y. Chimeric antigen receptor T cells applied to solid tumors. Front Immunol. 2022;13:984864.","journal-title":"Front Immunol"},{"key":"2946_CR3","doi-asserted-by":"publisher","first-page":"830","DOI":"10.1038\/s41577-024-01035-3","volume":"24","author":"JB Chung","year":"2024","unstructured":"Chung JB, Brudno JN, Borie D, Kochenderfer JN. Chimeric antigen receptor T cell therapy for autoimmune disease. Nat Rev Immunol. 2024;24:830\u201345.","journal-title":"Nat Rev Immunol"},{"key":"2946_CR4","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2023.1303935","volume":"14","author":"B Lickefett","year":"2023","unstructured":"Lickefett B, Chu L, Ortiz-Maldonado V, Warmuth L, Barba P, Doglio M, et al. Lymphodepletion - an essential but undervalued part of the chimeric antigen receptor T-cell therapy cycle. Front Immunol. 2023;14:1303935.","journal-title":"Front Immunol"},{"key":"2946_CR5","doi-asserted-by":"publisher","unstructured":"Lalic H, Aurer I, Batinic D, Visnjic D, Smoljo T, Babic A. Bendamustine: a review of pharmacology, clinical use and immunological effects (Review). Oncol Rep. 2022;47. https:\/\/doi.org\/10.3892\/or.2022.8325.","DOI":"10.3892\/or.2022.8325"},{"key":"2946_CR6","doi-asserted-by":"publisher","unstructured":"Bharadwaj S, Lau E, Hamilton MP, Goyal A, Srinagesh H, Jensen A, et al. Bendamustine is a safe and effective lymphodepletion agent for axicabtagene ciloleucel in patients with refractory or relapsed large B-cell lymphoma. J Immunother Cancer. 2024;12. https:\/\/doi.org\/10.1136\/jitc-2024-008975.","DOI":"10.1136\/jitc-2024-008975"},{"key":"2946_CR7","doi-asserted-by":"publisher","first-page":"916","DOI":"10.1016\/j.annonc.2022.05.521","volume":"33","author":"G Ghilardi","year":"2022","unstructured":"Ghilardi G, Chong EA, Svoboda J, Wohlfarth P, Nasta SD, Williamson S, et al. Bendamustine is safe and effective for lymphodepletion before tisagenlecleucel in patients with refractory or relapsed large B-cell lymphomas. Ann Oncol. 2022;33:916\u201328.","journal-title":"Ann Oncol"},{"key":"2946_CR8","doi-asserted-by":"publisher","first-page":"19","DOI":"10.1186\/s13045-024-01542-9","volume":"17","author":"G Ghilardi","year":"2024","unstructured":"Ghilardi G, Paruzzo L, Patel V, Svoboda J, Chong ER, Fardella E, et al. Efficacy and safety of bendamustine for lymphodepletion before lisocabtagene maraleucel. J Hematol Oncol. 2024;17:19.","journal-title":"J Hematol Oncol"},{"key":"2946_CR9","doi-asserted-by":"publisher","first-page":"653","DOI":"10.1182\/bloodadvances.2023011492","volume":"8","author":"G Ghilardi","year":"2024","unstructured":"Ghilardi G, Paruzzo L, Svoboda J, Chong EA, Shestov AA, Chen L, et al. Bendamustine lymphodepletion before axicabtagene ciloleucel is safe and associates with reduced inflammatory cytokines. Blood Adv. 2024;8:653\u201366.","journal-title":"Blood Adv"},{"key":"2946_CR10","doi-asserted-by":"publisher","first-page":"726.e721","DOI":"10.1016\/j.jtct.2024.03.015","volume":"30","author":"EA Chong","year":"2024","unstructured":"Chong EA, Chong ER, Therwhanger D, Nasta SD, Landsburg DJ, Barta SK, et al. Bendamustine as lymphodepletion for brexucabtagene autoleucel therapy of mantle cell lymphoma. Transplant Cell Ther. 2024;30:726.e721\u2013726.e728.","journal-title":"Transplant Cell Ther"},{"key":"2946_CR11","doi-asserted-by":"publisher","DOI":"10.1038\/s41408-023-00929-0","volume":"13","author":"S Sidana","year":"2023","unstructured":"Sidana S, Hosoya H, Jensen A, Liu L, Goyal A, Hovanky V, et al. Bendamustine vs. fludarabine\/cyclophosphamide lymphodepletion prior to BCMA CAR-T cell therapy in multiple myeloma. Blood cancer J. 2023;13:158.","journal-title":"Blood cancer J"},{"key":"2946_CR12","doi-asserted-by":"publisher","first-page":"3794","DOI":"10.1200\/JCO.20.01342","volume":"38","author":"CA Ramos","year":"2020","unstructured":"Ramos CA, Grover NS, Beaven AW, Lulla PD, Wu MF, Ivanova A, et al. Anti-CD30 CAR-T cell therapy in relapsed and refractory Hodgkin lymphoma. J Clin Oncol. 2020;38:3794\u2013804.","journal-title":"J Clin Oncol"},{"key":"2946_CR13","doi-asserted-by":"publisher","first-page":"1844","DOI":"10.1182\/blood-2025-1844","volume":"146","author":"S Ahmed","year":"2025","unstructured":"Ahmed S, Cao J, Mei M, Beitinjaneh A, Heslop H, Alasfour M, et al. Autologous CD30.CAR-T-cell therapy in patients with relapsed or refractory classical Hodgkin lymphoma \u2013 long term update of the chariot trial. Blood. 2025;146:1844.","journal-title":"Blood"},{"key":"2946_CR14","doi-asserted-by":"publisher","first-page":"405","DOI":"10.1182\/blood-2022-167504","volume":"140","author":"ACC Caballero Gonzalez","year":"2022","unstructured":"Caballero Gonzalez ACC, Escrib\u00e0-Garc\u00eda L, Montserrat R, Escudero-L\u00f3pez E, Pujol-Fern\u00e1ndez P, Ujald\u00f3n-Mir\u00f3 C, et al. Phase 1 clinical trial of memory-enriched academic HSP-CAR30 for the treatment of relapsed\/refractory Hodgkin lymphoma and CD30+ T-cell lymphoma: clinical and biological studies. Blood. 2022;140:405\u20137.","journal-title":"Blood"},{"key":"2946_CR15","doi-asserted-by":"publisher","first-page":"742","DOI":"10.1182\/blood-2021-148102","volume":"138","author":"NS Grover","year":"2021","unstructured":"Grover NS, Ivanova A, Moore DT, Cheng CJA, Babinec C, West J, et al. CD30-directed CAR-T cells co-expressing CCR4 in relapsed\/refractory Hodgkin lymphoma and CD30+ cutaneous T cell lymphoma. Blood. 2021;138:742.","journal-title":"Blood"},{"key":"2946_CR16","doi-asserted-by":"publisher","first-page":"45","DOI":"10.1056\/NEJMoa1804980","volume":"380","author":"SJ Schuster","year":"2019","unstructured":"Schuster SJ, Bishop MR, Tam CS, Waller EK, Borchmann P, McGuirk JP, et al. Tisagenlecleucel in adult relapsed or refractory diffuse large B-cell lymphoma. N Engl J Med. 2019;380:45\u201356.","journal-title":"N Engl J Med"},{"key":"2946_CR17","doi-asserted-by":"publisher","first-page":"3510","DOI":"10.1182\/blood-2023-189349","volume":"142","author":"I Landego","year":"2023","unstructured":"Landego I, Nemirovsky D, Devlin SM, Wills B, Parascondola A, Saldia A, et al. Comparison of bendamustine versus fludarabine\/ cyclophosphamide lymphodepletion in adult patients receiving CD19 CAR-T cell therapy. Blood. 2023;142:3510.","journal-title":"Blood"},{"key":"2946_CR18","doi-asserted-by":"publisher","first-page":"1751","DOI":"10.1002\/ajh.27069","volume":"98","author":"SY Ong","year":"2023","unstructured":"Ong SY, Pak S, Mei M, Wang Y, Popplewell L, Baird JH, et al. Bendamustine lymphodepletion is a well-tolerated alternative to fludarabine and cyclophosphamide lymphodepletion for axicabtagene ciloleucel therapy for aggressive B-cell lymphoma. Am J Hematol. 2023;98:1751\u201361.","journal-title":"Am J Hematol"},{"key":"2946_CR19","doi-asserted-by":"publisher","unstructured":"Rao UK, Majhail NS, Blunk B, Abernathy K, Bachier C, Bhushan V, et al. Comparative efficacy of bendamustine versus fludarabine\/cyclophosphamide for lymphodepletion before chimeric antigen receptor T-cell therapy in lymphoma. Transplant Cell Therapy. 2025, https:\/\/doi.org\/10.1016\/j.jtct.2025.03.012.","DOI":"10.1016\/j.jtct.2025.03.012"},{"key":"2946_CR20","doi-asserted-by":"publisher","unstructured":"Christodoulou I, Cooper K, Gao V, McFarquhar A, Dorritie K, Shlomchik WD. Comparative analysis of lymphodepletion regimens in CART-19 treatment for relapsed\/refractory diffuse large B cell lymphoma. Transplant Cell Therapy. 2025, https:\/\/doi.org\/10.1016\/j.jtct.2025.10.032.","DOI":"10.1016\/j.jtct.2025.10.032"},{"key":"2946_CR21","doi-asserted-by":"publisher","first-page":"71","DOI":"10.1182\/blood-2024-200269","volume":"144","author":"A Ali","year":"2024","unstructured":"Ali A, Ahmed N, Kim S, Bye M, Mirza S, Sieg AG, et al. Real world comparison of efficacy and safety of fludarabine-Versus bendamustine-Based lymphodepleting chemotherapy for CD19 chimeric antigen receptor (CAR) T-Cell therapy in relapse\/Refractory (r\/r) large B-Cell lymphoma (LBCL). Blood. 2024;144:71.","journal-title":"Blood"},{"key":"2946_CR22","first-page":"449.e441","volume":"29","author":"N Ahmed","year":"2023","unstructured":"Ahmed N, Wesson W, Mushtaq MU, Porter DL, Nasta SD, Brower J, et al. Patient characteristics and outcomes of outpatient tisagenlecleucel recipients for B cell non-Hodgkin lymphoma. Transplant Cell Ther. 2023;29:449.e441\u2013449.e447.","journal-title":"Transplant Cell Ther"},{"key":"2946_CR23","doi-asserted-by":"publisher","first-page":"4320","DOI":"10.1182\/bloodadvances.2024013239","volume":"8","author":"F Furqan","year":"2024","unstructured":"Furqan F, Bhatlapenumarthi V, Dhakal B, Fenske TS, Farrukh F, Longo W, et al. Outpatient administration of CAR T-cell therapies using a strategy of no remote monitoring and early CRS intervention. Blood Adv. 2024;8:4320\u20139.","journal-title":"Blood Adv"},{"key":"2946_CR24","doi-asserted-by":"publisher","unstructured":"Stokes J, Molina MS, Hoffman EA, Simpson RJ, Katsanis E. Immunomodulatory Effects of Bendamustine in Hematopoietic Cell Transplantation. Cancers; 2021;13. https:\/\/doi.org\/10.3390\/cancers13071702.","DOI":"10.3390\/cancers13071702"},{"key":"2946_CR25","doi-asserted-by":"publisher","DOI":"10.1002\/hem3.86","volume":"8","author":"G Iacoboni","year":"2024","unstructured":"Iacoboni G, S\u00e1nchez-Salinas MA, Rejeski K, Mart\u00edn-L\u00f3pez A, Kwon M, Navarro V, et al. Efficacy and safety of bendamustine-containing bridging therapy in R\/R LBCL patients receiving CD19 CAR T-cells. HemaSphere. 2024;8:e86.","journal-title":"HemaSphere"}],"container-title":["Bone Marrow Transplantation"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41409-026-02946-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41409-026-02946-6","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41409-026-02946-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,9,11]],"date-time":"2026-09-11T09:37:31Z","timestamp":1789119451000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41409-026-02946-6"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,6,22]]},"references-count":25,"journal-issue":{"issue":"9","published-print":{"date-parts":[[2026,9]]}},"alternative-id":["2946"],"URL":"https:\/\/doi.org\/10.1038\/s41409-026-02946-6","relation":{},"ISSN":["0268-3369","1476-5365"],"issn-type":[{"value":"0268-3369","type":"print"},{"value":"1476-5365","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,6,22]]},"assertion":[{"value":"22 February 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"6 May 2026","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"12 June 2026","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"22 June 2026","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare no competing interests.","order":1,"name":"Ethics","label":"Competing interests","group":{"name":"EthicsHeading","label":"Ethics"}}]}}